AusAm's Accumin Urine Test for Indicator of Potential Kidney Disease Offered by Specialty Laboratories.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- Proprietary Test Can Detect Microalbuminuria Up To 12 Years Earlier In Patients At-Risk For Developing Kidney Disease Kidney Disease Definition Kidney disease is a general term for any damage that reduces the functioning of the kidney. Kidney disease is also called renal disease. AusAm Biotechnologies, Inc. today announced that Specialty will now offer AusAm's FDA-cleared diagnostic, Accumin(TM) Direct Total Intact Albumin albumin (ălby  `mən) [Lat.,=white of egg], member of a class of water-soluble, heat-coagulating proteins. Albumins are widely distributed in plant and animal tissues, e.g. Assay (HPLC HPLC high-performance liquid chromatography. HPLC high performance liquid chromatography. HPLC High-performance liquid chromatography Lab instrumentation A highly sensitive analytic method in which analytes are placed )(TM) for detection of the protein albumin in urine. Accumin screens for abnormal levels of albumin in urine, a condition known as microalbuminuria, which could be an early sign of kidney disease. The American Diabetes Association The American Diabetes Association, or the ADA, is an American health organization providing diabetes research, information and advocacy. Founded in 1940, the American Diabetes Association conducts programs in all 50 states and the District of Columbia, reaching hundreds of recommends annual microalbumin tests for patients, such as diabetics, who are at risk of developing kidney disease. Diabetes and high blood pressure are the leading causes of kidney failure kidney failure or renal failure Partial or complete loss of kidney function. Acute failure causes reduced urine output and blood chemical imbalance, including uremia. Most patients recover within six weeks. . Individuals with a family history of kidney failure are also at risk. Clinical studies show that if detected in its early stages, severe kidney disease can be slowed, halted and in some cases reversed with common drug therapies such as angiotensin converting enzyme Noun 1. angiotensin converting enzyme - proteolytic enzyme that converts angiotensin I into angiotensin II angiotensin-converting enzyme, ACE peptidase, protease, proteinase, proteolytic enzyme - any enzyme that catalyzes the splitting of proteins into (ACE) inhibitors and angiotensin-2 receptor blockers (ARBs). "We believe the Accumin assay has very important clinical utility," said Ronald A. Blum, Ph.D., director of medical communications at Specialty Laboratories. "Its main advantage over traditional diagnostics is the early identification of kidney disease. This benefit is important for the health of the diabetic patient, allowing doctors to begin treatment in the early stages of disease and hopefully prevent complications. The Accumin assay also makes sense from a cost-benefit perspective. We believe this test may help reduce the need for more extensive and expensive medical testing and procedures. Specialty is very excited to be working with AusAm to deliver this innovative assay." Accumin provides the first and only direct, quantitative measurement for urinary urinary /uri·nary/ (u´ri-nar?e) pertaining to, containing, or secreting urine. u·ri·nar·y adj. 1. Relating to urine and its production, function, or excretion. 2. albumin. The direct method detects albumin and permits measurement of intact albumin not identified by current antibody and dye-binding tests. With Accumin, the potential for false negative results is reduced as compared to conventional commercial assays that fail to detect all intact albumin in the urine. "As one of the largest hospital-focused clinical labs in the country, Specialty maintains strong working relationships with a large number of physicians. This gives us access to a broader physician pool to effectively diagnose microalbuminuria," said James R. McCullough, chief executive officer of AusAm Biotechnologies. "Our goal is to make Accumin the standard of care for patients across the country, and we are pleased that Specialty is joining us in this effort." About Accumin(TM) Direct Total Intact Albumin Assay (HPLC)(TM) Cleared by the U.S. Food and Drug Administration in August 2003, Accumin was developed by AusAm Biotechnologies as a step-change improvement over conventional tests for microalbuminuria. Accumin uses common laboratory equipment to separate intact albumin from the other compounds in urine and directly determine its quantity. Accumin is relatively inexpensive and is reimbursable re·im·burse tr.v. re·im·bursed, re·im·burs·ing, re·im·burs·es 1. To repay (money spent); refund. 2. To pay back or compensate (another party) for money spent or losses incurred. by Medicare where medically reasonable and necessary. Patients who are interested in more information should consult their physicians about Accumin, or go to www.ausambiotech.com. Physicians interested in ordering this test should contact Specialty Laboratories at 800-421-7110 or visit their Web site at www.specialtylabs.com. About AusAm Biotechnologies, Inc. AusAm is a biotechnology research and development company commercializing both diagnostic and therapeutic products to identify and treat major diseases. Accumin(TM), AusAm's recently FDA-cleared diagnostic for the detection of intact albumin in urine, is the first direct test to measure a potential indicator of the beginning stages of kidney disease and it is currently offered by several reference laboratories and hospitals in the United States Lists of hospitals for each U.S. state:
Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement This press release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. with respect to management's beliefs about the business of AusAm in the future. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to the ability of AusAm to successfully implement the strategy of AusAm. AusAm undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unexpected results. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion